Scholar Rock Holding CORP 10-Q quarterly reports

Scholar Rock Holding Corporation's Q2 2026 Form 10-Q reveals continued net losses and operational expenses, with a focus on the resubmission of its apitegromab BLA to the FDA following a Complete Response Letter.

Scholar Rock Holding Corporation filed its Q1 2026 Form 10-Q, detailing a net loss of $105.5 million and a significant increase in G&A expenses, while also announcing the resubmission of its apitegromab BLA with a new PDUFA date.

Scholar Rock reported increased losses and a significant FDA Complete Response Letter for its lead SMA drug apitegromab, while securing additional debt financing and extending its cash runway into 2027.

Scholar Rock Holding Corporation reported increased net losses in Q2 2025 due to higher R&D and G&A expenses, while advancing its lead SMA drug, apitegromab, towards potential U.S. and European commercialization.

Scholar Rock Holding Corporation announces its Q1 2025 financial results, emphasizing the regulatory advancements of apitegromab for spinal muscular atrophy (SMA) and progress in its cardiometabolic and oncology programs.

Scholar Rock reports positive results from its Phase 3 SAPPHIRE trial for apitegromab in SMA and provides a financial update for the third quarter of 2024.

Scholar Rock's second quarter 2024 report details increased R&D spending, a net loss of $115.4 million for the first six months of the year, and ongoing clinical trials for their key drug candidates.

Scholar Rock Holding Corporation's first quarter 2024 results show increased research and development spending as the company advances its clinical programs.